A CARLAT PSYCHIATRY REFERENCE TABLE

FDA Approvals for TMS		
Year	Indication	Device
2008	Depressive episode unresponsive to a single medication trial	Neurostar (Neuronetics)
2013	Treatment-resistant depression (episode unresponsive to 2 medication trials)	Deep TMS (Brainsway)
2013	Pain associated with migraine headaches	Cerena TMS (eNeura Therapeutics)
2018	OCD with concurrent medication	Deep TMS (Brainsway)
2018	Express TMS	MagVita (MagVenture)
2020	Nicotine cessation	Deep TMS (Brainsway)
Pending	Bipolar depression (trials in progress)	Neurostar (Neuronetics)

From the Article:

"TMS Treatment for Depression: An Update" by Adam Strassberg, MD

The Carlat Psychiatry Report, Volume 19, Number 3, March 2021

www.thecarlatreport.com